Form 4: CRISPR Therapeutics Director Simeon George Granted 13,000 Stock Options
Insider Transaction Report (Form 4)
Simeon George, a Director at CRISPR Therapeutics AG (CRSP), has been granted 13,000 stock options with an exercise price of $38.57, vesting over 12 months.
Summary
- Simeon George, a Director of CRISPR Therapeutics AG, was granted 13,000 stock options on June 5, 2025.
- The exercise price for these options is $38.57 per common share.
- The options have an expiration date of June 5, 2035.
- The shares associated with the option grant will vest in 12 equal monthly installments, commencing on June 30, 2025.
- The final installment will vest on the earlier of the one-year anniversary of the grant date or the date of the 2026 Annual General Meeting of Shareholders.
Sentiment
Score: 7
Explanation: The document reports a routine insider transaction (stock option grant) which is generally viewed as a mild positive signal, indicating management's alignment with shareholder interests and confidence in future performance. It is not a major operational or financial update.
Positives
- The grant of stock options to a director can be viewed as a positive signal, indicating alignment of management's interests with shareholder value creation.
- The vesting schedule encourages long-term commitment from the director.
Future Outlook
The grant of stock options to a director suggests an expectation of future growth and value appreciation for CRISPR Therapeutics' common shares, as the options become more valuable if the stock price rises above the exercise price.
Industry Context
This Form 4 filing is a routine disclosure of an insider transaction, specifically the grant of stock options as part of director compensation. Such grants are common practice across all industries, including biotechnology, to incentivize leadership and align their financial interests with company performance.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | N/A | Simeon George | N/A | Simeon George is an existing director, this document reports a compensation grant. |
Stakeholder Impact
- Shareholders may view the option grant to a director as a positive sign of management's commitment and belief in the company's future prospects, potentially fostering confidence.
Next Steps
- The stock options will continue to vest in monthly installments, with the final vesting occurring by June 2026.
Key Dates
| Date | Description |
|---|---|
| 06/05/2025 | Date of stock option grant and earliest transaction date. |
| 06/06/2025 | Date the Form 4 was signed by the reporting person's attorney-in-fact. |
| 06/30/2025 | Start date for the 12 equal monthly vesting installments of the stock options. |
| 06/05/2026 | One-year anniversary of the grant date, which is a potential vesting completion date. |
| 06/05/2035 | Expiration date of the stock options. |
Keywords
CRISPR Therapeutics, CRSP, Stock Option, Insider Transaction, Form 4, Simeon George, Director Compensation, Gene Editing, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.